NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth
NeOnc Technologies (NASDAQ: NTHI) announced on November 4, 2025 that Amir Heshmatpour has been appointed Chief Executive Officer, effective immediately, while continuing as Executive Chairman.
Founder Dr. Thomas Chen will transition from CEO to focus on Chief Medical Officer and Chief Scientific Officer roles and clinical development of the company’s multi-Phase 2 programs. Recent corporate milestones cited include a $50 million strategic partnership with Quazar Investment, establishment of a UAE subsidiary (NuroMENA), expansion of the Scientific Advisory Board, and a NEO™ platform protected by more than 179 worldwide patents.
NeOnc Technologies (NASDAQ: NTHI) ha annunciato il 4 novembre 2025 che Amir Heshmatpour è stato nominato Amministratore Delegato, con effetto immediato, continuando nel ruolo di Presidente Esecutivo.
Il fondatore Dr. Thomas Chen passerà dal ruolo di CEO a concentrarsi sui ruoli di Direttore Medico e Direttore Scientifico e sullo sviluppo clinico dei programmi multi-Phase 2 dell’azienda. I recenti traguardi aziendali citati includono una partnership strategica da 50 milioni di dollari con Quazar Investment, l’istituzione di una filiale negli UAE (NuroMENA), l’espansione del Scientific Advisory Board e una piattaforma NEO™ protetta da più di 179 brevetti in tutto il mondo.
NeOnc Technologies (NASDAQ: NTHI) anunció el 4 de noviembre de 2025 que Amir Heshmatpour ha sido nombrado Director Ejecutivo, con efecto inmediato, mientras continúa como Presidente Ejecutivo.
El fundador Dr. Thomas Chen pasará de CEO a centrarse en los cargos de Director Médico y Director Científico y en el desarrollo clínico de los programas multidisciplinarios de fase 2 de la empresa. Los hitos corporativos recientes citados incluyen una asociación estratégica de 50 millones de dólares con Quazar Investment, el establecimiento de una filial en UAE (NuroMENA), la expansión del Consejo Asesor Científico y una plataforma NEO™ protegida por más de 179 patentes en todo el mundo.
NeOnc Technologies(NASDAQ: NTHI)가 2025년 11월 4일자로 Amir Heshmatpour를 CEO로 즉시 임명했고, Executive Chairman의 직책은 계속 수행합니다.
설립자 Dr. Thomas Chen은 CEO에서 물러나 최고의료책임자와 최고과학책임자 직무에 집중하고 회사의 다단계 2상 프로그램의 임상 개발에 전념할 예정입니다. 최근 언급된 회사의 이정표로는 Quazar Investment와의 5000만 달러 규모의 전략적 파트너십, UAE 자회사(NuroMENA) 설립, 과학 자문 위원회 확대, 그리고 전 세계적으로 179개 이상의 특허로 보호되는 NEO™ 플랫폼이 포함됩니다.
NeOnc Technologies (NASDAQ: NTHI) a annoncé le 4 novembre 2025 que Amir Heshmatpour a été nommé Chief Executive Officer, avec effet immédiat, tout en restant Président-Directeur Général.
Le fondateur Dr. Thomas Chen passera du poste de PDG à celui de Directeur Médical et Directeur Scientifique et se concentrera sur le développement clinique des programmes multi-Phase 2 de l’entreprise. Parmi les jalons récents cités figurent un partenariat stratégique de 50 millions de dollars avec Quazar Investment, l’établissement d’une filiale aux Émirats Arabes Unis (NuroMENA), l’expansion du Scientific Advisory Board et une plateforme NEO™ protégée par plus de 179 brevets dans le monde.
NeOnc Technologies (NASDAQ: NTHI) hat am 4. November 2025 bekannt gegeben, dass Amir Heshmatpour mit sofortiger Wirkung zum Chief Executive Officer ernannt wurde und weiterhin als Executive Chairman tätig bleibt.
Der Gründer Dr. Thomas Chen wird vom CEO-Posten zurücktreten und sich auf die Rollen Chief Medical Officer und Chief Scientific Officer sowie die klinische Entwicklung der mehrphasigen 2-Phase-Programme des Unternehmens konzentrieren. Zu den kürzlich genannten Unternehmensmeilensteinen gehören eine 50-Millionen-Dollar-Strategiepartnerschaft mit Quazar Investment, die Gründung einer Tochtergesellschaft in den VAE (NuroMENA), die Erweiterung des Scientific Advisory Board und eine NEO™-Plattform, die durch mehr als 179 Patente weltweit geschützt ist.
NeOnc Technologies (NASDAQ: NTHI) أعلن عن 4 نوفمبر 2025 أن أمير هشمتبور عيِّن الرئيس التنفيذي اعتباراً من فورياً، مع الاستمرار في منصب رئيس مجلس الإدارة التنفيذي.
سي الانتقال المؤسس الدكتور توماس تشين من دور المدير التنفيذي ليتركّز على مناصب المدير الطبي والمدير العلمي وعلى التطوير السريري لبرامج الشركة متعددة المراحل من فئة 2. وأشارت الإنجازات المؤسسية الأخيرة إلى شراكة استراتيجية بقيمة 50 مليون دولار مع Quazar Investment، وتأسيس فرع في الإمارات العربية المتحدة (NuroMENA)، وتوسيع مجلس المستشارين العلمي، ومنصة NEO™ المحمية بأكثر من 179 براءة اختراع حول العالم.
- $50 million strategic partnership with Quazar Investment
- Established NuroMENA UAE subsidiary under executive chairmanship
- 179+ worldwide patents covering the NEO™ platform
- CEO with track record: led $1.5B in IPOs and >$5B in deals
- CEO transition may create short-term execution or integration risks
- Reliance on the $50 million Quazar partnership for near-term financing
CALABASAS, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that its Board of Directors has appointed Amir Heshmatpour as Chief Executive Officer. Mr. Heshmatpour, who was appointed President in April, will assume the CEO role effective immediately, continuing to serve as Executive Chairman of the Board.
Dr. Thomas Chen, the company's founder, will transition from the CEO role to focus exclusively on his positions as Chief Medical Officer, Chief Scientific Officer, and member of the Board of Directors, ensuring his continued leadership over NeOnc's innovative scientific strategy and clinical development.
“It has been the honor of a lifetime to found NeOnc and lead it to this pivotal stage, and I have the utmost confidence that Amir is the ideal leader to steer the company into its future,” said Dr. Thomas Chen, Founder, CMO and CSO of NeOnc. “His proven expertise in corporate strategy, capital formation, and global business development is precisely what NeOnc needs as we advance our lead candidates toward commercialization. This transition allows me to dedicate my full attention to what I am most passionate about: accelerating our clinical trials and driving the science that has the potential to transform outcomes for patients with brain cancer.”
Since being appointed President, Mr. Heshmatpour has been instrumental in securing a series of transformative achievements for NeOnc. These include the finalization of a
“It is an extraordinary honor to lead NeOnc Technologies into its next phase of growth,” said Amir F. Heshmatpour, President, Chief Executive Officer, and Executive Chairman of NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). “With Dr. Chen now dedicating his full focus to accelerating patient enrollment and advancing our clinical trials, we are unlocking the full potential of our NEO™ platform, a scientific engine protected by more than 179 worldwide patents and pioneering the first-mover advantage in intranasal delivery for brain cancer and central nervous system diseases. Together, we are not just developing therapies, we are transforming the future of care for patients who have been told there are no options left. This is NeOnc’s moment to change the standard of care and to give hope back to those who need it most.”
Heshmatpour brings over 25 years of senior executive and board-level experience in business development, operations, finance, and M&A. He is the founder, chairman, and managing director of AFH Holdings & Advisory, where he has led IPO transactions totaling over
Previously, Heshmatpour served as Chairman and CEO of Metrophone Telecommunications, which he founded in 1994. Under his leadership, Metrophone completed 17 acquisitions and grew annual revenues to over
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com.
Important Cautions Regarding Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com
FAQ
Who is the new CEO of NeOnc Technologies (NTHI) and when did the change occur?
What role will Dr. Thomas Chen hold after the November 4, 2025 leadership change at NTHI?
How much is the strategic partnership announced by NeOnc (NTHI)?
What is NuroMENA and how does it relate to NeOnc (NTHI)?
How many patents protect NeOnc’s NEO™ platform as disclosed on November 4, 2025?
What executive experience does Amir Heshmatpour bring to NeOnc (NTHI)?
